Verve Therapeutics (VERV) Competitors

Verve Therapeutics (NASDAQ:VERV) and Beam Therapeutics (NASDAQ:BEAM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Which has higher earnings & valuation, VERV or BEAM?

Verve Therapeutics has higher earnings, but lower revenue than Beam Therapeutics. Verve Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verve Therapeutics	$32.33M	30.69	-$198.71M	-$2.11	-5.27
Beam Therapeutics	$63.52M	28.38	-$376.74M	-$4.50	-3.96

Is VERV or BEAM more profitable?

Verve Therapeutics has a net margin of -303.64% compared to Beam Therapeutics' net margin of -661.31%. Verve Therapeutics' return on equity of -35.81% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verve Therapeutics	-303.64%	-35.81%	-27.57%
Beam Therapeutics	-661.31%	-43.15%	-31.06%

Which has more risk & volatility, VERV or BEAM?

Verve Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500.

Do institutionals and insiders hold more shares of VERV or BEAM?

97.1% of Verve Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 19.3% of Verve Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Do analysts prefer VERV or BEAM?

Verve Therapeutics currently has a consensus target price of $14.57, suggesting a potential upside of 30.92%. Beam Therapeutics has a consensus target price of $48.45, suggesting a potential upside of 171.91%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Beam Therapeutics is more favorable than Verve Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verve Therapeutics	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Beam Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.07

Does the media favor VERV or BEAM?

In the previous week, Beam Therapeutics had 9 more articles in the media than Verve Therapeutics. MarketBeat recorded 10 mentions for Beam Therapeutics and 1 mentions for Verve Therapeutics. Beam Therapeutics' average media sentiment score of 0.66 beat Verve Therapeutics' score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verve Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beam Therapeutics beats Verve Therapeutics on 9 of the 17 factors compared between the two stocks.